Collagen XXIII: A potential biomarker for the detection of primary and recurrent non-small cell lung cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 5, 2010, Pages 1362-1372

  Spivey, Kristin A ^a   Banyard, Jacqueline ^a   Solis, Luisa M ^e   Wistuba, Ignacio I ^e   Barletta, Justine A ^d   Gandhi, Leena ^c   Feldman, Henry A ^b   Rodig, Scott J ^d   Chirieac, Lucian R ^d   Zetter, Bruce R ^a  

^a Vascular Biology Program   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 23; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; URINALYSIS; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COLLAGEN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952018170     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1095     Document Type: Article

References (37)

1. Cancer Facts & Figures. Atlanta: American Cancer Society; 2009.
2. World Health Organization classification of tumours. In: Travis WD, Brambilla E, Muller-Hemelink HK, Harris CC, editors. Pathology and Genetics of Tumous of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007;7:778-790 (Pubitemid 47463669)
4. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:740-753
5. Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007;132:1-19S.
6. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181 (Pubitemid 46316032)
7. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-205
8. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-552
9. Chan HP, Lewis C, Thomas PS. Exhaled breath analysis: novel approach for early detection of lung cancer. Lung Cancer 2009;63:164-168
10. Phillips M. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999;353:1930-1933 (Pubitemid 29255706)
11. Banyard J, Bao L, Zetter BR. Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells. J Biol Chem 2003;278:20989-20994 (Pubitemid 36806408)
12. Banyard J, Bao L, Hofer MD, et al. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases. Clin Cancer Res 2007;13:2634-2642 (Pubitemid 46788030)
13. Hashimoto T, Wakabayashi T, Watanabe A, et al. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J 2002;21:1524-1534
14. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 Gene amplification in lung adenocarcinoma. J Cell Mol Med 2008;13:1977-1986
15. Koch M, Veit G, Stickler S, et al. Expression of type XXIII collagen mRNA and protein. J Biol Chem 2006;281:21546-21557 (Pubitemid 44115491)
16. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006;1:331-348
17. Veit G, Zimina EP, Franzke CW, et al. Shedding of collagen XXIII is mediated by furin and depends on the plasma membrane microenvironment. J Biol Chem 2007;282:27424-27435 (Pubitemid 47501942)
18. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75:1509-1514 (Pubitemid 27196874)
19. Mulshine JL. Current issues in lung cancer screening. Oncology (Williston Park) 2005;19:1724-30; discussion 30-31
20. Lam S, MacAulay C, leRiche JC, Palcic B. Detection and localization of early lung cancer by fluorescence bronchoscopy. Cancer 2000;89:2468-2473
21. Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol 2009;22:1032-1043
22. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-830 (Pubitemid 33108152)
23. Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009;37:178-183
24. Sheu CC, Chang MY, Chang HC, et al. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer. Oncology 2006;70:203-211
25. Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008;9:676-682 (Pubitemid 351878053)
26. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-262 (Pubitemid 41779062)
27. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 2007;13:284-289 (Pubitemid 46847293)
28. Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol 2008;23:693-700. (Pubitemid 351552354)
29. Gallardo E, Navarro A, Vinolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009;30:1903-1909
30. Iizasa T, Chang H, Suzuki M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 2004;10:5361-5366 (Pubitemid 39100472)
31. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998;58:1395-1399 (Pubitemid 28193598)
32. Patz EF, Jr., Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE II. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;25:5578-5583
33. Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009;69:2990-2995
34. Huang LJ, Chen SX, Huang Y, et al. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 2006;54:87-94.
35. Huang LJ, Chen SX, Luo WJ, Jiang HH, Zhang PF, Yi H. Proteomic analysis of secreted proteins of non-small cell lung cancer. Ai Zheng 2006;25:1361-1367
36. Cho WC. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 2007;61:515-519 (Pubitemid 47570078)
37. Lopez de Cicco R, Bassi DE, Page R, Klein-Szanto AJ. Furin expression in squamous cell carcinomas of the oral cavity and other sites evaluated by tissue microarray technology. Acta Odontol Latinoam 2002;15:29-37.